Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zu Vedolizumab mit Tofacitinib bei Erwachsenen mit Colitis ulcerosa (UC)

22. Oktober 2026 aktualisiert von: Takeda

Eine offene, einarmige, multizentrische Phase-4-Studie zur Bewertung der Induktion von Reaktion und Remission einer dualen gezielten Vedolizumab-Therapie mit Tofacitinib bei erwachsenen Patienten mit mittelschwerer bis schwerer aktiver Colitis ulcerosa

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with vedolizumab alone after the double treatment.

All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks.

Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Detaillierte Beschreibung

The drugs being tested in this study are called Vedolizumab and Tofacitinib. Vedolizumab and Tofacitinib dual targeted therapy is being tested to treat people with moderate to severe UC who have experienced inadequate response, loss of response or intolerance to no more than 2 prior tumor necrosis factor (TNF) antagonists. This study will look at the clinical remission in people who take Vedolizumab and Tofacitinib dual targeted therapy.

The study will enroll approximately 60 participants. All the participants will be enrolled in a single treatment group to receive dual targeted treatment with Vedolizumab and Tofacitinib for the first 8 weeks:

Vedolizumab 300 mg + Tofacitinib 10 mg

Only those participants who show a clinical response at Week 8 will transition to Vedolizumab monotherapy for 44 weeks.

This multi-center trial will be conducted in the United States and Canada. The overall duration of the study is up to 76 weeks. Participants will be followed up for 26 weeks after the last dose of the study drug for safety.

Studientyp

Interventionell

Einschreibung (Geschätzt)

60

Phase

  • Phase 4

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Ontario
      • Barrie, Ontario, Kanada, L4M 7G1
        • Barrie GI Associates Inc.
      • London, Ontario, Kanada, N6A 5A5
        • London Health Sciences Centre
      • Mississauga, Ontario, Kanada, L5M 7N4
        • West GTA Endoscopy Inc.
      • North Bay, Ontario, Kanada, P1B 2H3
        • Viable Clinical Research - North Bay
      • North York, Ontario, Kanada, M6A3B4
        • Toronto Immune and Digestive Health Institute Inc. (TIDHI)
      • Oakville, Ontario, Kanada, L6L 5L7
        • ABP Research Services Corp.
      • Oshawa, Ontario, Kanada, L1J 0C7
        • Taunton Surgical Centre
      • Vaughan, Ontario, Kanada, L4L 4Y7
        • Toronto Digestive Disease Associates (TDDA) Inc.
    • Quebec
      • Montreal, Quebec, Kanada, H3G 1A4
        • The Research Institute of the McGill University Health Centre
    • Alabama
      • Dothan, Alabama, Vereinigte Staaten, 36301
        • Digestive Health Specialsits
    • Arizona
      • Sun City, Arizona, Vereinigte Staaten, 85351
        • GI Alliance Sun City
    • California
      • Los Angeles, California, Vereinigte Staaten, 90048
        • Cedars-Sinai Medical Center
      • Newport Beach, California, Vereinigte Staaten, 92663
        • Hoag Hospital Newport Beach
    • Florida
      • Orlando, Florida, Vereinigte Staaten, 32803
        • Endoscopic Research Inc
      • Tampa, Florida, Vereinigte Staaten, 33615
        • Alliance Clinical Research of Tampa, LLC
    • Georgia
      • Roswell, Georgia, Vereinigte Staaten, 30076
        • Gastroenterology Consultants, P.C.
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60637
        • University of Chicago Medicine
    • Kansas
      • Kansas City, Kansas, Vereinigte Staaten, 66160
        • University of Kansas Medical Center
    • Kentucky
      • Louisville, Kentucky, Vereinigte Staaten, 40202
        • University of Louisville
    • Louisiana
      • Metairie, Louisiana, Vereinigte Staaten, 70006
        • GI Alliance
      • New Orleans, Louisiana, Vereinigte Staaten, 70112
        • Tulane University
    • Maryland
      • Chevy Chase, Maryland, Vereinigte Staaten, 20815
        • Capital Digestive Care - MGG Group - Chevy Chase Clinical Research
    • Michigan
      • Ypsilanti, Michigan, Vereinigte Staaten, 48197
        • Huron Gastroenterology Associates, P.C.
    • Minnesota
      • Plymouth, Minnesota, Vereinigte Staaten, 55446
        • MNGI Digestive Health, PA
    • Missouri
      • Kansas City, Missouri, Vereinigte Staaten, 64111
        • Mid-America Gastro-Intestinal Consultants
      • Liberty, Missouri, Vereinigte Staaten, 64068
        • BVL Clinical Research
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Washington University School of Medicine
    • New York
      • New York, New York, Vereinigte Staaten, 10016
        • NYU Langone Health
      • New York, New York, Vereinigte Staaten, 10065
        • Weill Cornell Medical College- New York Presbyterian Hospital
    • North Carolina
      • Asheville, North Carolina, Vereinigte Staaten, 28801
        • Digestive Health Partners
      • Chapel Hill, North Carolina, Vereinigte Staaten, 27599
        • University of North Carolina
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45627
        • University of Cincinnati
      • Columbus, Ohio, Vereinigte Staaten, 43202
        • Ohio Gastroenterology group, Inc.
      • Westlake, Ohio, Vereinigte Staaten, 44145
        • Gastro Intestinal Research Institute of Northern Ohio, LLC.
    • Pennsylvania
      • Wexford, Pennsylvania, Vereinigte Staaten, 15090
        • Allegheny Health Network
    • Rhode Island
      • Providence, Rhode Island, Vereinigte Staaten, 02094
        • University Gastroenterology
    • South Dakota
      • Rapid City, South Dakota, Vereinigte Staaten, 57701
        • Sanford Health Research
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • The University of Texas Health Science Center at Houston
      • Mansfield, Texas, Vereinigte Staaten, 76063
        • GI Alliance - Mansfield
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • Gastroenterology Research of San Antonio, LLC
      • Southlake, Texas, Vereinigte Staaten, 76092
        • Texas Digestive Disease Consultants (TDDC), Southlake
      • Tyler, Texas, Vereinigte Staaten, 75701
        • Tyler Research Institute, LLC
      • Webster, Texas, Vereinigte Staaten, 77598
        • GI Alliance - Webster
    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84108
        • University of Utah Health
    • Washington
      • Tacoma, Washington, Vereinigte Staaten, 98405
        • Washington Gastroenterology- GIA

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Has a confirmed diagnosis of UC established at least 3 months prior to screening, by clinical and endoscopic evidence and corroborated by a histopathology report.
  2. Has moderately to severely active UC as determined by a complete Mayo score [including PGA] of 6 to 12 with a rectal bleeding subscore ≥1 and a centrally assessed endoscopic subscore ≥2 at screening.
  3. Has evidence of UC extending proximally to the rectum [≥15 centimeter (cm) of involved colon].
  4. Participants with extensive colitis or pancolitis of >8 years duration or left sided colitis >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months of the initial screening visit.
  5. Participants with a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factors must be up to date on colorectal cancer surveillance.
  6. Has demonstrated an inadequate response to, loss of response to, or intolerance to at least 1, but no more than 2 TNFα antagonists. Determination of inadequate response, loss of response, or intolerance is based upon investigator's clinical judgment. Participants who discontinued TNFα antagonist therapy for reasons other than failure or intolerance (eg, pregnancy) may be eligible after discussion with the medical monitor.

Note: After the interim analysis, participants with inadequate response, loss of response, or intolerance to conventional UC therapy per standard of care treatment without prior exposure to biologics may be enrolled if deemed appropriate. Determination of inadequate response, loss of response, or intolerance is based upon investigator's clinical judgment. Participants who discontinued biologics for reasons other than failure or intolerance (eg, pregnancy) may be eligible after discussion with the Medical Monitor. If using corticosteroids must be on a stable dose of oral corticosteroids up to a maximum of 40 mg daily of prednisone or 9 mg daily of budesonide, or equivalent for at least 2 weeks prior to screening endoscopy and must be willing to follow a mandatory taper of corticosteroids.

Exclusion Criteria:

Gastrointestinal Exclusion criteria:

  1. Has any of the following UC-related complications:

    1. Acute severe UC.
    2. The participant has had extensive colonic resection, subtotal or total colectomy.
    3. The participant has clinical evidence of abdominal abscess or toxic megacolon.
    4. The participant has an ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
    5. Short bowel syndrome.
  2. Has Crohn's colitis, indeterminate colitis, ischemic colitis, nonsteroidal anti-inflammatory drug (NSAID) induced colitis, idiopathic colitis (i.e, colitis not consistent with UC), radiation colitis, microscopic colitis, colonic mucosal dysplasia, or untreated bile acid malabsorption. Participants with a history of colonic mucosal dysplasia are also excluded.

  3. Has uncontrolled primary sclerosing cholangitis.

Infectious Disease Exclusion Criteria:

  1. Has any evidence of an active systemic infection during screening. Participants with nonsystemic infections (eg, active fungal infection of nail beds) may be eligible, if in the opinion of the investigator, inclusion of the participant will not interfere with the collection or interpretation of study results and poses no risk to the participant.

  2. Has active or latent tuberculosis (TB), regardless of treatment history, as evidenced by any of the following:

    1. History of TB.
    2. A diagnostic TB test performed during screening that is positive, as defined by:

    i. A positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests or ii. A tuberculin skin test reaction ≥10 mm (≥5 mm in participants receiving the equivalent of >15 mg daily prednisone).

  3. A positive test for hepatitis B virus (HBV).

  4. A positive test for hepatitis C virus (HCV).

  5. Evidence of, or treatment for, Clostridium difficile infection or other intestinal pathogen during screening. Participants who test positive for C. difficile or other intestinal pathogens at screening and receive treatment may be enrolled or rescreened (if required) following confirmation of infection resolution.

  6. Evidence of active Cytomegalovirus (CMV) infection at screening.

Medication exclusion criteria:

  1. Has received immunomodulators (eg, 6-mercaptopurine, azathioprine, and methotrexate) within 4 weeks prior to first dose or immunosuppressants (eg, cyclosporine, tacrolimus) within 8 weeks prior to first dose.

  2. Any medicinal product, herbal medication, or natural health product which might interfere with cytochrome P450 genotype 3A4 (CYP3A4) within 2 weeks prior to enrollment, except for any CYP3A4 modulator used to treat a C. difficile or an intestinal pathogen infection at screening.

  3. Has received any of the following medical therapies for UC:

    1. IV antibiotics within 8 weeks prior to enrollment.
    2. Any rectal therapy for treatment of UC within 2 weeks prior to screening endoscopy.
    3. Chronic NSAID use defined as daily use for >2 consecutive weeks (Note: occasional use [<2 consecutive weeks] of NSAIDs and acetaminophen [<100 mg daily] for headache, arthritis, myalgias, or menstrual cramps and chronic low dose aspirin use [81-162.5 mg daily] for cardiovascular prophylaxis are permitted).
  4. Has received a live vaccine within 4 weeks prior to first dose.

General Exclusion Criteria:

  1. Has any of the following cardiovascular or thrombotic conditions:

    1. Recent (within past 6 months) cerebrovascular accident, myocardial infarction, or coronary stenting.
    2. Recent (within past 6 months) moderate to severe congestive heart failure (New York Heart Association class III or IV).
    3. Prior history of thrombotic events, including deep vein thrombosis and pulmonary embolism.
    4. Known inherited conditions that predispose to hypercoagulability.
  2. History of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.

  3. A surgical procedure requiring general anesthesia within 3 months prior to screening or is planning to undergo major surgery during the study period.

  4. Any investigational procedure ≤4 weeks prior to screening that, in the investigator's opinion, may interfere with interpretation of study results.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Vedolizumab 300 mg + Tofacitinib 10 mg

Participants will receive Vedolizumab 300 mg, intravenous (IV) infusion, at Week 0, Week 2 and Week 6 along with Tofacitinib 10 mg, tablets, orally, twice daily from Week 0 to Week 8. Participants with clinical response at Week 8 will transition to receive vedolizumab 300 mg IV infusion every 8 weeks (Q8W) through Week 46.

Vedolizumab IV infusions

Andere Namen:
  • Entyvio
  • MLN0002

Tofacitinib Tablets

Andere Namen:
  • Xeljanz
  • CP-690
  • CP-550

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants Achieving Clinical Remission at Week 8 Based on Complete Mayo Score
Zeitfenster: At Week 8

Clinical remission based on complete Mayo Score is where a participant achieves complete Mayo Score ≤2 points with no individual subscore >1 at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a Physician's Global Index (PGA) and Mayo endoscopic findings (MES). Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants Achieving Clinical Remission at Week 52 Based on Complete Mayo Score
Zeitfenster: At Week 52

Clinical remission based on complete Mayo Score is where a participant achieves complete Mayo Score ≤2 points with no individual subscore >1 at Week 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 52
Percentage of Participants Achieving Clinical Remission at Weeks 8, 14, and 26 Based on Partial Mayo Score
Zeitfenster: At Weeks 8, 14 and 26

Clinical remission based on complete Mayo Score is where a participant achieves partial Mayo Score ≤2 points with no individual subscore >1. Partial Mayo Score consists of 3 variables of the Mayo Clinic Score: stool frequency, rectal bleeding and PGA. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease. These scores are summed to give a total score range of 0 to 9 where higher scores indicate maximum disease activity.

At Weeks 8, 14 and 26
Percentage of Participants Achieving Clinical Response at Weeks 2, 6, 8, 14, 26 and 52 Based on Complete or Partial Mayo Score
Zeitfenster: At Weeks 2, 6, 8, 14, 26, and 52

Clinical response based on complete Mayo Score is where a participant achieves a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline or a partial Mayo score of ≥2 points and ≥25% from baseline, if the complete Mayo score was not performed at the visit with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Weeks 2, 6, 8, 14, 26, and 52
Percentage of Participants Achieving Clinical Remission at Week 8 and Week 52 Based on Modified Mayo Score
Zeitfenster: At Weeks 8 and 52

Clinical remission based on modified Mayo Score is where a participant achieves component modified Mayo score of ≤2 with modified MES ≤1, rectal bleeding = 0, and stool frequency ≤1. Modified Mayo Score consists of 3 variables: stool frequency, rectal bleeding and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease. These scores are summed to give a total score range of 0 to 9 where higher scores indicate maximum disease activity.

At Weeks 8 and 52
Percentage of Participants With Endoscopic Improvement at Week 8 and Week 52 Based on Modified Mayo Endoscopic Subscore (MMES)
Zeitfenster: At Weeks 8 and 52

Endoscopic improvement based on modified mayo endoscopic score is where participants achieve MMES ≤1 point. The subscale is graded from 0 to 3 based on the findings on endoscopy were 0= Normal appearance of mucosa, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher scores indicate more severe disease.

At Weeks 8 and 52
Percentage of Participants With Durable Clinical Remission at Week 8 and Week 52
Zeitfenster: At Week 8 and Week 52

Durable clinical remission is defined as the clinical remission at Week 8 and Week 52. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Weeks 8 and 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8 and Week 52
Percentage of Participants Using Oral Corticosteroids at Baseline Achieving Clinical Remission at Week 8
Zeitfenster: At Week 8

Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8
Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 8
Zeitfenster: At Week 8

Corticosteroid-free clinical remission is where a participant achieves corticosteroid-free clinical remission at Week 8. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8
Percentage of Participants Using Oral Corticosteroids at Baseline Achieving Clinical Remission at Week 52
Zeitfenster: At Week 52

Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 52
Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 52
Zeitfenster: At Week 52

Corticosteroid-free clinical remission is where a participant achieves corticosteroid-free clinical remission at Week 52, and was off corticosteroids at least 3 months prior to Week 52. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 52
Percentage of Participants Achieving Clinical Response at Week 8
Zeitfenster: At Week 8

Clinical response based on complete Mayo Score is where a participant achieves a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8
Percentage of Participants With Endoscopic Improvement at Week 52
Zeitfenster: At Week 52

Endoscopic improvement based on modified mayo score is where participants achieve MMES ≤1 point. The subscale is graded from 0 to 3 based on the findings on endoscopy were 0= Normal appearance of mucosa, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher scores indicate more severe disease.

At Week 52
Percentage of Participants With Histological Remission Based on Geboes Score at Week 52
Zeitfenster: At Week 52

Histological remission is defined as Geboes score <2 at Week 52. The Geboes score is a histological grading system for assessing histological disease activity in UC. The Geboes score evaluates 7 histological features. It consists of 6 grades (0-6). Each of the grades is divided into subgrades, based on the severity of tissue abnormalities or the extent of inflammatory cell infiltration. The Geboes score ranges from 0.0 to 5.4, and higher grades are indicative of more severe disease activity.

At Week 52
Change in C-Reactive Protein Levels (CRP) From Baseline
Zeitfenster: Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52

CRP is a useful marker of inflammation in participants with inflammatory bowel disease (IBD). In participants with UC, elevated CRP has been associated with severe clinical activity.

Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52
Change in Fecal Calprotectin Concentrations From Baseline
Zeitfenster: Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52

Fecal calprotectin is a biomarker for intestinal inflammatory activity.

Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline
Zeitfenster: At Weeks 8, 26 and 52

The IBDQ is an instrument used to assess quality of life in adult participants with inflammatory bowel disease (IBD). It includes 32 questions on 4 domains of Health-Related Quality-of-Life (HRQOL): Bowel Systems (10 items), Emotional Function (12 items), Social Function (5 items), and Systemic Function (5 items). Participants are asked to recall symptoms and quality of life from the last 2 weeks and rate each item on a 7-point Likert scale (1=worst to 7=best). A total IBDQ score is calculated by summing the scores from each domain; the total IBDQ score ranges from 32 to 224, with lower scores reflecting worse HRQOL. A positive change from Baseline indicates improvement.

At Weeks 8, 26 and 52
Change in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Score From Baseline
Zeitfenster: At Weeks 8, 26 and 52

The FACIT-F is a validated, 13-item questionnaire to assess fatigue in participants with a variety of chronic illnesses, including participants with IBD. Items are rated on a 5-point Likert scale and the total score ranges from 0 to 52 with lower scores representing greater fatigue.

At Weeks 8, 26 and 52
Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
Zeitfenster: Up to 76 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention.

Up to 76 weeks
Number of Participants With Clinically Significant Change in Vital Signs From Baseline
Zeitfenster: Up to 76 weeks

Vital signs will include body temperature, respiratory rate, blood pressure (resting more than 5 minutes), and pulse (resting more than 5 minutes).

Up to 76 weeks
Number of Participants With Clinically Significant Physical Examination Findings
Zeitfenster: At Baseline and From Week 14 to Week 72

A baseline physical examination (defined as the assessment before first dose of study medication) will consist of the following body systems: general appearance; HEENT (head, eyes, ears, nose, and throat); cardiovascular system; respiratory system; gastrointestinal system; dermatologic system; extremities; musculoskeletal system; nervous system; lymph nodes; and other. All subsequent physical examinations will assess clinically significant changes from the assessment prior to first dose examination.

At Baseline and From Week 14 to Week 72
Number of Participants With Markedly Abnormal Laboratory Values
Zeitfenster: Up to 76 weeks

Standard laboratory tests will include clinical chemistry, hematology, coagulation and urinalysis.

Up to 76 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Study Director, Takeda

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

12. Juni 2024

Primärer Abschluss (Geschätzt)

9. Juli 2027

Studienabschluss (Geschätzt)

9. Juli 2027

Studienanmeldedaten

Zuerst eingereicht

18. Oktober 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

18. Oktober 2023

Zuerst gepostet (Tatsächlich)

23. Oktober 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

26. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD-Sharing-Zugriffskriterien

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren